Menu

Novo Nordisk’s Ozempic Gets EU Regulator Endorsement to Reduce Kidney Risks

Novo Nordisk said the European Union’s drug regulator supports a label expansion of its Ozempic diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease in adults with Type 2 diabetes.

The European Medicines Agency’s backing comes after a trial earlier this year showed that Ozempic slows the progression of chronic kidney disease and cuts the risk of kidney failure, heart attack, stroke and

Scroll to Top